Submitted by sandy craine on Mon, 15/07/2013 - 1:25pm
By Dave Levitan | July 12, 2013
While tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) in recent years, prognosis of the disease and prediction of response to those treatments has fallen behind. A new study validates a simple prognostic score known as the EUTOS score, featuring only two variables, as a useful tool in prediction of therapeutic effects of TKIs, and especially of imatinib(Drug information on imatinib).
By Dave Levitan | July 12, 2013
While tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) in recent years, prognosis of the disease and prediction of response to those treatments has fallen behind. A new study validates a simple prognostic score known as the EUTOS score, featuring only two variables, as a useful tool in prediction of therapeutic effects of TKIs, and especially of imatinib(Drug information on imatinib).
Submitted by sandy craine on Wed, 03/07/2013 - 12:44pm
Zosia Chustecka
Jul 02, 2013
The European Commission has granted marketing authorization to ponatinib (Iclusig, Ariad Pharmaceuticals) as an orphan drug for use in certain leukemia patients who have stopped responding to or cannot tolerate other therapies.
Zosia Chustecka
Jul 02, 2013
The European Commission has granted marketing authorization to ponatinib (Iclusig, Ariad Pharmaceuticals) as an orphan drug for use in certain leukemia patients who have stopped responding to or cannot tolerate other therapies.
Submitted by sandy craine on Mon, 01/07/2013 - 12:13pm
Michele Baccarani1,*, Michael W. Deininger2, Gianantonio Rosti3, Andreas Hochhaus4, Simona Soverini3, Jane F. Apperley5, Francisco Cervantes6, Richard E. Clark7, Jorge E. Cortes8, François Guilhot9, Henrik Hjorth-Hansen10, Timothy P. Hughes11, Hagop M. Kantarjian8, Dong-Wook Kim12, Richard A. Larson13, Jeffrey H. Lipton14, François-Xavier Mahon15, Giovanni Martinelli3, Jiri Mayer16, Martin C. Müller17, Dietger Niederwieser18, Fabrizio Pane19, Jerald P. Radich20, Philippe Rousselot21, Giuseppe Saglio22, Susanne Saußele17, Charles Schiffer23, Richard Silver24, Bengt Simonsson25, Juan-Luis Steegmann26, John M. Goldman27, and Rüdiger Hehlmann17
Michele Baccarani1,*, Michael W. Deininger2, Gianantonio Rosti3, Andreas Hochhaus4, Simona Soverini3, Jane F. Apperley5, Francisco Cervantes6, Richard E. Clark7, Jorge E. Cortes8, François Guilhot9, Henrik Hjorth-Hansen10, Timothy P. Hughes11, Hagop M. Kantarjian8, Dong-Wook Kim12, Richard A. Larson13, Jeffrey H. Lipton14, François-Xavier Mahon15, Giovanni Martinelli3, Jiri Mayer16, Martin C. Müller17, Dietger Niederwieser18, Fabrizio Pane19, Jerald P. Radich20, Philippe Rousselot21, Giuseppe Saglio22, Susanne Saußele17, Charles Schiffer23, Richard Silver24, Bengt Simonsson25, Juan-Luis Steegmann26, John M. Goldman27, and Rüdiger Hehlmann17
Submitted by sandy craine on Mon, 17/06/2013 - 3:18pm
The Chronic Myelogenous Leukemia (CML) Society of Canada is pleased to provide open access to the paper, “Treating Chronic Myeloid Leukemia - Improving Management Through Understanding of the Patient Experience”.
The Chronic Myelogenous Leukemia (CML) Society of Canada is pleased to provide open access to the paper, “Treating Chronic Myeloid Leukemia - Improving Management Through Understanding of the Patient Experience”.
Submitted by sandy craine on Wed, 12/06/2013 - 10:45am
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)
2013 ASCO Annual Meeting
Abstract Number: 7054^
Citation: J Clin Oncol 31, 2013 (suppl; abstr 7054^)
Author(s):
Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, Surapol Issaragrilsil, Anna G. Turkina, Juan Luis Steegmann, Jose L. Lopez, Chiaki Nakaseko, Matt E. Kalaycio, Francoise Huguet, Charisse N. Kemp, Xiaolin Fan, Hans D. Menssen, Hagop M. Kantarjian, Andreas Hochhaus; University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy; Centre for Cancer Biology, SA Pathology, University of Adelaide, Adelaide, Australia; The University of Chicago, Chicago, IL; Mahidol University, Siriraj Hospital, Bangkok, Thailand; Hematology Research Center, Moscow, Russia; Hospital Universitario de la Princesa, Madrid, Spain; Banco Municipal de Sangre, Dpt. Clinicas Hematologicas, Esq. Pirineos, Caracas, DC, Venezuela; Chiba University Hospital, Department of Hematology, Chiba, Japan; Cleveland Clinic, Cleveland, OH; Hospital de Purpan, Toulouse, France; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; The University of Texas MD Anderson Cancer Center, Houston, TX; Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)
2013 ASCO Annual Meeting
Abstract Number: 7054^
Citation: J Clin Oncol 31, 2013 (suppl; abstr 7054^)
Author(s):
Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, Surapol Issaragrilsil, Anna G. Turkina, Juan Luis Steegmann, Jose L. Lopez, Chiaki Nakaseko, Matt E. Kalaycio, Francoise Huguet, Charisse N. Kemp, Xiaolin Fan, Hans D. Menssen, Hagop M. Kantarjian, Andreas Hochhaus; University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy; Centre for Cancer Biology, SA Pathology, University of Adelaide, Adelaide, Australia; The University of Chicago, Chicago, IL; Mahidol University, Siriraj Hospital, Bangkok, Thailand; Hematology Research Center, Moscow, Russia; Hospital Universitario de la Princesa, Madrid, Spain; Banco Municipal de Sangre, Dpt. Clinicas Hematologicas, Esq. Pirineos, Caracas, DC, Venezuela; Chiba University Hospital, Department of Hematology, Chiba, Japan; Cleveland Clinic, Cleveland, OH; Hospital de Purpan, Toulouse, France; Novartis Pharmaceuticals Corp, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; The University of Texas MD Anderson Cancer Center, Houston, TX; Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany
Submitted by sandy craine on Wed, 12/06/2013 - 10:38am
2013 ASCO Annual Meeting
Abstract Number: 7079
Citation: J Clin Oncol 31, 2013 (suppl; abstr 7079)
Author(s):
Hemant Malhotra, Pratibha Sharma, Shipra Bhargava, Om Singh Rathode, Bharti Malhotra, Vikram Gota; Birla Cancer Center, SMS Medical College Hospital, Jaipur, India; Advanced Research Lab, SMS Medical College, Jaipur, India; Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Center, Navi Mumbai, India
Background: One of the reasons proposed for suboptimal responses in Chronic Myeloid Leukemia (CML) patients receiving standard-dose Imatinib has been low blood levels of the drug. Our study aimed to determine the correlation between mean trough Imatinib plasma levels and molecular response in CML chronic phase patients at our centre. We also attempted to compare imatinib plasma levels in patients receiving Gleevec (Novartis) versus patients who were on the generic version of the drug.
2013 ASCO Annual Meeting
Abstract Number: 7079
Citation: J Clin Oncol 31, 2013 (suppl; abstr 7079)
Author(s):
Hemant Malhotra, Pratibha Sharma, Shipra Bhargava, Om Singh Rathode, Bharti Malhotra, Vikram Gota; Birla Cancer Center, SMS Medical College Hospital, Jaipur, India; Advanced Research Lab, SMS Medical College, Jaipur, India; Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Center, Navi Mumbai, India
Background: One of the reasons proposed for suboptimal responses in Chronic Myeloid Leukemia (CML) patients receiving standard-dose Imatinib has been low blood levels of the drug. Our study aimed to determine the correlation between mean trough Imatinib plasma levels and molecular response in CML chronic phase patients at our centre. We also attempted to compare imatinib plasma levels in patients receiving Gleevec (Novartis) versus patients who were on the generic version of the drug.
Submitted by sandy craine on Wed, 05/06/2013 - 10:53am
" The tyrosine kinase inhibitors (TKIs) have irrevocably changed the care of chronic myeloid leukemia (CML) patients, dramatically changing the natural history of this disease.1-4 With multiple TKIs available, we now have an “embarrassment of riches” in treatment options. Below are some common questions and clinically relevant answers regarding treatment.
" The tyrosine kinase inhibitors (TKIs) have irrevocably changed the care of chronic myeloid leukemia (CML) patients, dramatically changing the natural history of this disease.1-4 With multiple TKIs available, we now have an “embarrassment of riches” in treatment options. Below are some common questions and clinically relevant answers regarding treatment.
Submitted by sandy craine on Wed, 05/06/2013 - 10:03am
Significance
Cancer stem cells (CSCs) frequently acquire the ability to self-renew and persist in their hosts by coopting normal stem cell programs. Blast crisis (BC) chronic myeloid leukemia is a prototypic example, as the acquired activation of β-catenin signaling that enables BC CSC function is also important in normal hematopoietic stem cell maintenance. In identifying eIF4E phosphorylation by the MNK kinases as a necessary step in β-catenin activation in BC CSCs, but not normal hematopoietic stem cells, we define a therapeutic target in BC. Our studies suggest that clinical trials with MNK kinase inhibitors are warranted in BC chronic myeloid leukemia.
Significance
Cancer stem cells (CSCs) frequently acquire the ability to self-renew and persist in their hosts by coopting normal stem cell programs. Blast crisis (BC) chronic myeloid leukemia is a prototypic example, as the acquired activation of β-catenin signaling that enables BC CSC function is also important in normal hematopoietic stem cell maintenance. In identifying eIF4E phosphorylation by the MNK kinases as a necessary step in β-catenin activation in BC CSCs, but not normal hematopoietic stem cells, we define a therapeutic target in BC. Our studies suggest that clinical trials with MNK kinase inhibitors are warranted in BC chronic myeloid leukemia.
Submitted by sandy craine on Sat, 01/06/2013 - 9:14pm
Sebastian Francis, Claire Lucas, Steven Lane, Lihui Wang, Sarah Watmough, Katy Knight, Jo Bell, Mohammed Kaleel-Rahman, Edwin Lee, David O’Brien, Nauman M. Butt, Walid Sadik, Lally De Soysa, Jim R.C. Seale, Rahuman Salim, Richard E. Clark
Sebastian Francis, Claire Lucas, Steven Lane, Lihui Wang, Sarah Watmough, Katy Knight, Jo Bell, Mohammed Kaleel-Rahman, Edwin Lee, David O’Brien, Nauman M. Butt, Walid Sadik, Lally De Soysa, Jim R.C. Seale, Rahuman Salim, Richard E. Clark
Submitted by sandy craine on Sun, 12/05/2013 - 7:23pm
Susan Branford1,2,3, David T. Yeung1,2,4, David M. Ross2,4,5, Jodi A. Prime1, Chani R. Field1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Brad Sullivan1, Nancy E. Briggs6, Mark Hertzberg7,8, John F. Seymour7,9, John Reynolds10, and Timothy P. Hughes2,4,7
Susan Branford1,2,3, David T. Yeung1,2,4, David M. Ross2,4,5, Jodi A. Prime1, Chani R. Field1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Brad Sullivan1, Nancy E. Briggs6, Mark Hertzberg7,8, John F. Seymour7,9, John Reynolds10, and Timothy P. Hughes2,4,7
Pages
